Les troubles de l'humeur: approche pharmacologique

In the treatment of depression, the major objective is remission. Unfortunately, in clinical trials as in naturalistic studies, complete remission rate is very low. Consequences of partial remission or non-response to treatment are well known particularly in terms of risk of relapse, chronicity and quality of life impairment. During the 2006-2007 period, we participated to studies that tend to bring complementary responses to key issues in major depression, and particularly remission and socio-economic correlates of depression, but also the role of serotonin noradrenaline reuptake inhibitors in the perspective of remission.